

Anti-TNFSF7/CD27L/CD70 Antibody (Vorsetuzumab mafodotin)

Introduction

Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule and a cytotoxic tubulin polymerization inhibitor. It is used to treat renal cell carcinoma.

Product parameters

Alternative Names	Vorsetuzumab mafodotin
Target Accession	P32970
Target	TNFSF7 / CD27L / CD70
CAS number	1165741-01-4
Molecular Weight	146.1 kDa
Host	CHO
Reactivity	Human
Conjugation	MMAF
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized humanCD70-His at 2 ug/mL (30 μ L/well) can bind Anti-TNFSF7/CD27L/CD70 Antibody (Vorsetuzumab mafodotin) with the EC50 of 0.007612 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

